(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE
Prostate Cancer
University of ChicagoSmall moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 59/ 100
Competitive context
513 Active assets in the Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avodart Bay State Clinical Trials, Inc. | Phase 4 | BBB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
Degarelix Bayer | Phase 4 | BBB |
PROPOFOL Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
AVOLVE Masonic Cancer Center, University of Minnesota | Phase 4 | BB |
View all 50 →
Same molecule, other indications
(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →